NO20016380L - Procedure for preventing tumor growth - Google Patents

Procedure for preventing tumor growth

Info

Publication number
NO20016380L
NO20016380L NO20016380A NO20016380A NO20016380L NO 20016380 L NO20016380 L NO 20016380L NO 20016380 A NO20016380 A NO 20016380A NO 20016380 A NO20016380 A NO 20016380A NO 20016380 L NO20016380 L NO 20016380L
Authority
NO
Norway
Prior art keywords
tumor growth
procedure
preventing tumor
preventing
ltbr
Prior art date
Application number
NO20016380A
Other languages
Norwegian (no)
Other versions
NO20016380D0 (en
Inventor
Daniela N Maennel
Thomas Hehlgans
Carola Seitz
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999129488 external-priority patent/DE19929488A1/en
Priority claimed from DE2000104447 external-priority patent/DE10004447A1/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20016380D0 publication Critical patent/NO20016380D0/en
Publication of NO20016380L publication Critical patent/NO20016380L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fremgangsmåte for forhindring av betennelser, autoimmune sykdommer og tumorvekst ved å undertrykke LTBR-mediert aktivering, beskrives.Methods for preventing inflammation, autoimmune diseases and tumor growth by suppressing LTBR-mediated activation are described.

NO20016380A 1999-06-28 2001-12-27 Procedure for preventing tumor growth NO20016380L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999129488 DE19929488A1 (en) 1999-06-28 1999-06-28 Treatment of inflammation, autoimmune disease and tumors by suppressing activation mediated by the lymphotoxin beta-receptor
DE2000104447 DE10004447A1 (en) 2000-02-03 2000-02-03 Treatment of inflammation, autoimmune disease and tumors by suppressing activation mediated by the lymphotoxin beta-receptor
PCT/EP2000/005738 WO2001000228A1 (en) 1999-06-28 2000-06-21 Method for preventing tumoral growth

Publications (2)

Publication Number Publication Date
NO20016380D0 NO20016380D0 (en) 2001-12-27
NO20016380L true NO20016380L (en) 2001-12-27

Family

ID=26004148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016380A NO20016380L (en) 1999-06-28 2001-12-27 Procedure for preventing tumor growth

Country Status (20)

Country Link
EP (1) EP1189626B1 (en)
JP (1) JP3822822B2 (en)
KR (1) KR20020016852A (en)
CN (1) CN1359297A (en)
AT (1) ATE410180T1 (en)
AU (1) AU5406000A (en)
BG (1) BG106246A (en)
BR (1) BR0012006A (en)
CA (1) CA2376920A1 (en)
DE (1) DE50015391D1 (en)
ES (1) ES2313893T3 (en)
HK (1) HK1047045A1 (en)
HU (1) HUP0201804A2 (en)
IL (1) IL147180A0 (en)
MX (1) MXPA01013367A (en)
NO (1) NO20016380L (en)
PL (1) PL353057A1 (en)
SK (1) SK18852001A3 (en)
TR (1) TR200103841T2 (en)
WO (1) WO2001000228A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134994A0 (en) 2000-03-09 2001-05-20 Yeda Res & Dev Coupled two way clustering analysis of data
CN1761680A (en) 2002-12-26 2006-04-19 武田药品工业株式会社 Metastin derivative and use thereof
CN101863971A (en) 2004-06-25 2010-10-20 武田药品工业株式会社 Metastin derivatives and use thereof
CA2624730A1 (en) * 2005-10-04 2007-04-12 The John Hopkins University Compositions and methods for treating inflammation
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (en) 2005-12-22 2013-02-21 Takeda Pharmaceutical Metastin derivatives and use thereof
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EE05213B1 (en) * 1996-10-25 2009-10-15 Biogen, Incorporated Use of a L mphotoxin β receptor (LT-β-R) blocking agent and a pharmaceutical composition comprising a LT-β-R blocking agent and a CD40L blocking agent
CN1287853C (en) * 1998-01-30 2006-12-06 拜奥根Idec马萨诸塞公司 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway

Also Published As

Publication number Publication date
HK1047045A1 (en) 2003-02-07
ES2313893T3 (en) 2009-03-16
CA2376920A1 (en) 2001-01-04
EP1189626A1 (en) 2002-03-27
BR0012006A (en) 2002-03-12
JP2003503359A (en) 2003-01-28
SK18852001A3 (en) 2002-12-03
AU5406000A (en) 2001-01-31
IL147180A0 (en) 2002-08-14
WO2001000228A1 (en) 2001-01-04
DE50015391D1 (en) 2008-11-20
JP3822822B2 (en) 2006-09-20
CN1359297A (en) 2002-07-17
PL353057A1 (en) 2003-10-06
HUP0201804A2 (en) 2002-09-28
NO20016380D0 (en) 2001-12-27
MXPA01013367A (en) 2002-07-02
ATE410180T1 (en) 2008-10-15
TR200103841T2 (en) 2002-06-21
EP1189626B1 (en) 2008-10-08
BG106246A (en) 2002-10-31
KR20020016852A (en) 2002-03-06

Similar Documents

Publication Publication Date Title
CA2388646A1 (en) Methods and compositions utilizing quinazolinones
MY140767A (en) Compounds, methods and compositions
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60040981D1 (en) TREATMENT WITH ANTI-ErbB2 ANTIBODIES
DE69805237D1 (en) Tumor necrosis associated receptor, TR4
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
EA200001129A2 (en) METHOD OF OBTAINING 4-CARBOXYAMINO-2-SUBSTITUTE-1,2,3,4-TETRAHYDROCHINOLINE
AU2079901A (en) Thrombopoietin mimetics
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2000066528A3 (en) Quinones for treatment of diseases
AU2003252025A1 (en) Compounds, compositions, and methods
NO20016380L (en) Procedure for preventing tumor growth
WO2004034972A3 (en) Compounds, compositions, and methods
AU7847800A (en) Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
WO2001035995A3 (en) Tr3-specific binding agents and methods for their use
WO2004032879A3 (en) Compounds, compositions, and methods
AU4643501A (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
ZA200203166B (en) Treatment of cancer.
AU2607999A (en) Sustained release implant, methods for preparation thereof and for treating cancer
AU2202301A (en) Cd45 inhibitors
AU6234000A (en) Methods for treating autoimmune diseases
AU2001291993A1 (en) Method for producing human anti-thymocyte immunoglobulins
AU2616201A (en) Cancer treatment method
AU3503200A (en) Compounds, compositions, and methods for photodynamic therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application